



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Supply chain vulnerabilities of high-use pharmaceuticals: An explorative cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2025-099697
Article Type:	Original research
Date Submitted by the Author:	23-Jan-2025
Complete List of Authors:	Postma, Doerine; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology; Royal Dutch Association for the Advancement of Pharmacy De Smet, Peter AGM; Radboud University, Departments of Clinical Pharmacy and IQ Healthcare, Institute for Health Sciences Mantel-Teeuwisse, Aukje; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology Leufkens, Hubert; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology Notenboom, Kim; Medicines Evaluation Board
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, Pharmacists

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

<b>Title</b>	Supply chain vulnerabilities of high-use pharmaceuticals: an explorative cohort study
<b>Authors' names</b>	Doerine J Postma (0000-0001-7129-1624), Peter AGM De Smet (0000-0003-1762-6547), Aukje K Mantel-Teeuwisse (0000-0002-8782-0698), Hubert GM Leufkens (0000-0002-7175-1499), Kim Notenboom (0009-0007-2795-134X)
<b>Authors names and positions</b> <b>Address for each author</b>	<p><b>Doerine J Postma</b>, researcher, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Peter AGM De Smet</b>, emeritus professor of pharmaceutical care, Departments of Clinical Pharmacy and IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, the Netherlands</p> <p><b>Aukje K Mantel-Teeuwisse</b>, professor of pharmacy and global health, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Hubert GM Leufkens</b>, emeritus professor of pharmaceutical policy and regulation, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Kim Notenboom</b>, research associate, Medicines Evaluation Board, PO Box 8275, 3503 RG Utrecht, the Netherlands</p>
<b>Corresponding author</b>	Correspondence to: d.j.postma@uu.nl. Doerine J Postma, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands, (0031)30 253 7324

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**SUPPLY CHAIN VULNERABILITIES OF HIGH-USE PHARMACEUTICALS: AN EXPLORATIVE COHORT STUDY**

*Doerine J Postma, \*1,2 Peter AGM De Smet, 3 Aukje K Mantel-Teeuwisse, 1 Hubert GM Leufkens, 1 Kim Notenboom4*

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
1.
2.
3.
4.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands*
- Royal Dutch Pharmacists Association, The Hague, the Netherlands*
- Radboud University Medical Centre, Radboud Institute for Health Sciences, Departments of IQ Healthcare and Clinical Pharmacy, Nijmegen, the Netherlands*
- Dutch Medicines Evaluation Board, Utrecht, the Netherlands*

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

\*Corresponding author: Doerine J Postma | Universiteitsweg 99, 3584 CG Utrecht, The Netherlands, d.j.postma@uu.nl, (0031)30 253 7324

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**ABSTRACT**

**Objectives** – To assess the upstream pharmaceutical supply chains of ten high-use pharmaceuticals to detect vulnerabilities that may increase the risk of medicine shortages

**Design** – Explorative cohort study

**Setting** – Dutch outpatient setting in 2022

**Participants** – A total of 407 authorised medicinal products for ten pharmaceutical substances with the largest number of outpatients

**Main outcome measures** – The diversity of active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP) manufacturers, their geographic locations and the interdependencies between these manufacturers and marketing authorisation holders (MAHs)

**Results** – For the 407 authorised medicinal products, 50 of the 90 API manufacturing sites were in Asia, and 38 in Europe. For five pharmaceutical substances, most of the API sites were located outside Europe. Of the 128 FPP manufacturing sites, 94 were in Europe, and 31 in Asia. For all ten substances, at least 47% of FPP sites were located in Europe.

API manufacturing for 122 of the 407 products (30%) was entirely performed outside Europe, and FPP manufacturing for 66 of the 407 products (16%). For four substances, more than half of the products depended on API manufacturing outside Europe.

The number of distinct API and FPP manufacturing sites per substance was at least four. For amoxicillin, 16 of the 32 products (50%) entirely depended on one and the same API site. For omeprazole, 39 of the 85 products (46%) entirely depended on one and the same FPP site.

MAHs applied dual sourcing for API and FPP manufacturing for 61 (15%) of the authorised medicinal products. For three pharmaceutical substances, none of the authorised medicinal products listed at least two API and FPP manufacturing sites.

**Conclusion** – Our study of the supply chains of high-use pharmaceutical substances indicates the need for a granular assessment of the interdependencies between MAHs, API and FPP manufacturers to identify upstream supply chain vulnerabilities.

## STRENGTHS AND LIMITATIONS

- This study offers insights into the pharmaceutical supply chains, focussing on the diversity of API and FPP manufacturers and their geographic locations.
- The use of Dutch Medicines Evaluation Board database to analyse the research question is ideal since this is the official source to register this information.
- We visualised the ten upstream pharmaceutical supply chains using Sankey diagrams, illustrating the complex interdependencies among stakeholders.
- Our cohort of ten pharmaceutical substances is unlikely to be representative of all medicines.

## SUMMARY BOX

### What is already known on this topic

- The pharmaceutical supply chain is highly complex, involves multiple interdependent stakeholders, relies on a global network, and lacks transparency.
- Upstream supply-related issues (i.e. manufacturing and quality) are among the main causes of medicine shortages.

### What this study adds

- A minority of the high-use authorized medicinal products studied were entirely depended on API and FPP manufacturing sites outside of Europe. However, for some pharmaceutical substances, most of the authorized medicinal products entirely relied on non-European API manufacturers.
- A viable market with different API and FPP manufacturers was established for all studied substances, but there was an overdependency on one API or FPP manufacturer for some substances.
- Dual sourcing for API and FPP manufacturing was adopted for only a limited share of authorised medicinal products, and for some substances, none of the authorised products listed dual sourcing for both the API and FPP.

INTRODUCTION

A continuous supply of quality-assured, safe, effective, and affordable medicines is essential for a well-functioning health system. [1] Until the beginning of the 21<sup>st</sup> century the availability of medicines did not significantly concern high-income countries. Then, discrepancies between supply and demand began to frequently emerge. [2-4] Currently, medicine shortages are ‘the new normal’. [5, 6]. The main causes of medicine shortages are related to manufacturing and quality issues [7, 8], which are part of the upstream supply chain, from active pharmaceutical ingredient (API) to FPP manufacturing and packaging, rather than the downstream distribution. [9] Despite the increased focus on the availability of medicines during the COVID-19 pandemic, shortages further increased post-COVID-19, [10-12] underscoring the necessity of addressing the ongoing challenges in the pharmaceutical supply chain.

The pharmaceutical supply chain is complex, involving multiple interdependent stakeholders and relying on a global distribution network. MAHs are responsible for their authorised medicinal products and for the qualification and selection of the involved (number of) manufacturers. MAHs often rely on manufacturers located worldwide to produce APIs and finished pharmaceutical products (FPPs). [13] MAHs may decide to manufacture APIs and FPPs in-house, which offers control over quality, quantity, and timelines, thus providing the flexibility to rapidly respond to manufacturing problems requiring expertise and resources. However, manufacturing generic products is increasingly outsourced, enlarging external dependency and introducing complexity into the upstream supply chain. [14] A much-raised additional concern is the geographical location and concentration of manufacturing sites, particularly in Asia. [15-17] Studies on manufacturing sites and their geographic locations are limited. For the API market in general, we found data regarding the geographic distribution of manufacturers in relation to turnover. According to the researchers, API manufacturing for the European market is predominantly situated in Asia (56%), followed by Western Europe (24%) and North America (12%), with limited contributions from the rest of the world (8%). [18]

The supply chain may be disturbed by manufacturing issues, natural disasters, or geopolitical disputes. Problems with API availability may disrupt FPP manufacturing, impact the marketing of authorised medicinal products by MAHs, prohibit dispensing by the pharmacist, and ultimately restrict patient access. A robust supply chain would prevent a problem occurring at one point in the supply from causing disruptions elsewhere. To enhance supply chain resilience, ensuring supplier diversity is considered crucial. [19, 20] For a viable market, a supplier base of at least three different API and FPP manufacturers per pharmaceutical substance is considered desirable according to participants at a WHO-convened technical consultation. [21] Dual sourcing strategies per authorised medicinal product – establishing two suppliers for a given ingredient or component in a regulatory product dossier – is also a well-known measure. [20, 22]

Supply chain resilience is in the spotlight of global pharmaceutical policies. [17, 23] The European Commission is analysing supply chains of medicines on the EU list of critical medicines to identify vulnerabilities. Foreseen EU policy measures to strengthen these supply chains include regulatory flexibilities and recommendations to diversify manufacturers and increase Europe’s manufacturing capacity. [24, 25] Insight into interdependencies among stakeholders – such as the

number of API manufacturers supplying FPP manufacturers and the subsequent number of FPP manufacturers supplying different MAHs, along with their geographic locations – can help to identify supply chain vulnerabilities. Although geographic concentration is often reported as an issue, and medicine shortages and pharmaceutical supply chain vulnerabilities have been linked by some researchers [26-29], no studies have specifically analysed the interdependencies among stakeholders in the upstream pharmaceutical supply chain.

This research aimed to assess pharmaceutical supply chains by evaluating the diversity of API and FPP manufacturers, their geographic locations and the interdependencies between MAHs and these manufacturers. We selected ten pharmaceutical substances with the largest number of outpatients in the Netherlands since supply disruptions of these medicines may affect a significant share of the population.



**METHODS**

**Study population and data collection**

For this explorative cohort study, ten pharmaceutical substances with the largest number of patients in the Dutch outpatient setting were chosen because the number of patients is a key element determining a shortage’s impact. [30] All treatments were counted equally, regardless of therapeutic use and treatment duration; thus, we did not take the total annual volume into account. The ten high-use pharmaceutical substances in 2021 originated from the database of the Dutch Foundation for Pharmaceutical Statistics [31, 32], which contains complete information on the Dutch outpatient setting including the outpatient pharmacies in hospitals. The pharmaceutical substances were classified according to the WHO’s Anatomical Therapeutic Chemical (ATC) classification fifth level (i.e. APIs). [33] We included pharmaceutical substances containing one or a fixed combination of two active components.

The medicinal products containing these ten pharmaceutical substances authorised in the Netherlands, along with their responsible MAHs and the involved API and FPP manufacturers and their geographic locations, were identified using the Dutch Medicines Evaluation Board (MEB) [34] database in July 2022. We excluded products for parenteral use such as solution for injection or infusion since these are mainly prescribed in hospital settings.

**Study outcomes and data analysis**

For the authorised medicinal products, a researcher (DJP) obtained distinct MAHs, API and FPP manufacturers, and geographic locations of the manufacturers at the country and continent levels. The geographic locations were limited to API and FPP manufacturing sites because they are more geographically bound than MAHs, and regulatory requirements are involved when changing them. [35]

We calculated the median number of authorised medicinal products per MAH and the interquartile range (IQR) and range. For authorised medicinal products, we plotted the number of API versus FPP manufacturing sites on a bubble chart. For products containing two pharmaceutical substances, we only plotted the manufacturers of the substances with the fewest API manufacturers because it represented the worst case and, thus, greatest overall vulnerability.

We mapped the pharmaceutical supply chains using Sankey diagrams containing nodes and links to visualise stakeholder interdependencies. The nodes represent the API manufacturer, the FPP manufacturer, authorised medicinal products, and the MAH, respectively. The links show their interactions. The width of the nodes is proportional to the number of links; a wider node means more interaction with next-stage stakeholders.

Descriptive statistics present the characteristics of authorised medicinal products and manufacturing sites. Graphics were created using Microsoft Office 365 Excel and Adobe Illustrator (Sankey diagrams).

**Patient and Public Involvement**

Neither patients nor the public were involved in the conception, design, or execution of this study.

## RESULTS

The ten pharmaceutical substances with the largest number of patients in the outpatient setting in the Netherlands included two ATC fifth-level substances containing more than two active components. These two substances were replaced by the next two ATC fifth-level substances that met the inclusion criteria. For the selected substances, 407 medicinal products for outpatient use were authorised in the Netherlands in July 2022 (Figure 1). In total, 37% of the Dutch population (6.5 million people) received a prescription for one or more of the selected medicinal products (see supplementary table S1).

### Figure 1: Selection of pharmaceutical substances with the largest number of patients in the Dutch outpatient setting and the related authorised medicinal products for analysis

The 407 products included authorised off-patent medicinal products predominantly intended for oral use (378; 93%), with a few for inhalation (21; 5%) or rectal use (8; 2%). The number of authorised medicinal products per pharmaceutical substance ranged from 21 for levonorgestrel/ethinylestradiol and salbutamol to 85 products for omeprazole. The 407 authorised medicinal products were the responsibility of 70 distinct MAHs (see supplementary table S1), and their manufacturing involved 90 distinct API sites and 128 distinct FPP sites. Three manufacturing sites produced APIs as well as FPPs. In our cohort of 407 products, the 70 MAHs were responsible for a median of three (IQR: 2–6) authorised medicinal products (range: 1–42). Of the 70 MAHs, 49 had marketing authorisations for products for one of the ten pharmaceutical substances. Three MAHs had marketing authorisations for products for nine of the ten pharmaceutical substances.

### API manufacturing

The 90 API manufacturers for the 407 authorised medicinal products were mostly located in Asia (50; 55%), a large minority in Europe (38; 42%), and rarely in the Americas (2; 3%) (see Table 1 and supplementary figure S1). The number of distinct API manufacturing sites per pharmaceutical substance ranged from four for levonorgestrel/ethinylestradiol to 17 for pantoprazole. For desloratadine, diclofenac, metoprolol, pantoprazole, and simvastatin, more than half of the API manufacturing sites were located outside Europe (54%–82%). For amoxicillin and omeprazole, the API sites were equally divided outside and within Europe. For the remaining three substances, a minority of the sites were located outside Europe (range: 0%–40%) thus for the majority within Europe (60–100%). For all pharmaceutical substances at least two API manufacturing sites were located in Europe.

Among the 407 authorised medicinal products, 122 entirely relied on APIs manufactured outside of Europe (Table 1). For four substances (desloratadine, diclofenac, pantoprazole, and simvastatin), the authorised medicinal products predominantly relied on only API manufacturing sites outside of Europe (range: 52–66%). For colecalciferol, metoprolol and omeprazole, the API manufacturing sites were outside and within Europe. For the remaining three substances, the minority of the products relied on API sites outside Europe (range: 0–25%). The number of authorised

medicinal products per substance specified per country of the manufacturing site is displayed in supplementary figure S1.

**Table 1: Number and geographic location (continent) of active pharmaceutical ingredient (API) manufacturing sites and related medicinal products**

pharmaceutical substance	number of API manufacturing sites per continent			number of related authorised medicinal products per continent			
	total	Europe	other continents	total	Europe	Europe and other continents*	other continents
overall	90	38 (42%)	52 (58%)	407	146 (36%)	139 (34%)	122 (30%)
amoxicillin	6	3 (50%)	3 (50%)	32	24 (75%)		8 (25%)
colecalfiferol	5	3 (60%)	2 (40%)	82	47 (57%)	18 (22%)	17 (21%)
desloratadine	15	3 (20%)	12 (80%)	34		15 (44%)	19 (56%)
diclofenac	8	3 (38%)	5 (62%)	29	7 (24%)	3 (10%)	19 (66%)
levonorgestrel / ethinylestradiol	4	4 (100%)		21	21 (100%)		
metoprolol	13	6 (46%)	7 (54%)	34	13 (38%)	16 (47%)	5 (15%)
omeprazole	12	6 (50%)	6 (50%)	85	14 (16%)	56 (66%)	15 (18%)
pantoprazole	17	4 (24%)	13 (76%)	33		16 (48%)	17 (52%)
salbutamol	6	5 (83%)	1 (17%)	21	20 (95%)		1 (5%)
simvastatin	11	2 (18%)	9 (82%)	36		15 (42%)	21 (58%)

\* The regulatory dossier for an authorised medicinal product may list several API manufacturers on different continents.

**FPP manufacturing**

The 128 FPP manufacturing sites for the 407 authorised medicinal products were mainly situated in Europe (94; 74%), to a lesser extent in Asia (31; 24%), and rarely in the Americas (3; 2%) (see Table 2 and supplementary figure S1). The number of distinct FPP manufacturing sites per pharmaceutical substance ranged from seven for levonorgestrel/ethinylestradiol to 23 for simvastatin. For pantoprazole a small majority (53%) of FPP sites were located outside Europe and for amoxicillin the FPP sites were equally divided outside and within Europe. For the other eight substances, the minority of FPP sites were located outside Europe (range: 0–48%). For all ten pharmaceutical substances at least five FPP manufacturing sites were present in Europe.

Of the related authorised medicinal products, 66 of the 407 (16%) were entirely manufactured outside Europe (Table 2). For all substances, the minority of the authorised medicinal products relied solely on FPP manufacturing outside Europe (range: 0–38%). The number of authorised medicinal products per substance specified per country of the manufacturing site is displayed in supplementary figure S1.

**Table 2: Number and geographic location (continent) of finished pharmaceutical product (FPP) manufacturing sites and related medicinal products**

pharmaceutical substance	Number of FPP manufacturing sites per continent			Number of related authorised medicinal products per continent			
	Total	Europe	other continents	total	Europe	Europe and other continents*	other continents
overall	128	94 (73%)	34 (17%)	407	286 (70%)	55 (14%)	66 (16%)

amoxicillin	10	5 (50%)	5 (50%)	32	23 (72%)		9 (28%)
colecalfiferol	21	17 (81%)	4 (19%)	82	56 (68%)	14 (17%)	12 (15%)
desloratadine	21	15 (71%)	6 (29%)	34	20 (59%)	1 (3%)	13 (38%)
diclofenac	19	16 (84%)	3 (16%)	29	24 (83%)	3 (10%)	2 (7%)
levonorgestrel/ ethinylestradiol	7	6 (86%)	1 (14%)	21	18 (86%)		3 (14%)
metoprolol	18	14 (78%)	4 (22%)	34	25 (74%)	5 (15%)	4 (12%)
omeprazole	10	7 (70%)	3 (30%)	85	77 (91%)	3 (3%)	5 (6%)
pantoprazole	17	8 (47%)	9 (53%)	33	14 (42%)	14 (42%)	5 (16%)
salbutamol	11	11 (100%)		21	21 (100%)		
simvastatin	23	12 (52%)	11 (48%)	36	8 (22%)	15 (42%)	13 (36%)

\* The regulatory dossier for an authorised medicinal product may list several FPP manufacturers on different continents.

## Diversity of manufacturers

The regulatory dossiers of 346 of the 407 products (85%) listed either one API manufacturing and multiple FPP sites (83; 20%), one FPP manufacturing and multiple API sites (157; 39%), or one API and one FPP site (106; 26%) (Figure 2). For 61 authorised medicinal products (15%), at least two API and FPP sites were listed. For four substances, most authorised medicinal products (69%–78%) relied on one API manufacturing site. For eight substances, more than half of the authorised medicinal products (52%–95%) relied on one FPP manufacturing site (see supplementary table S2). For amoxicillin, colecalfiferol, and levonorgestrel/ethinylestradiol, none of the authorised products listed two or more manufacturing sites for the APIs and FPPs (see supplementary figure S2). For simvastatin and pantoprazole, most of the authorised medicinal products (both 61%) listed at least two manufacturing sites for the APIs and FPPs.

**Figure 2: Number of authorised medicinal products with the corresponding number of manufacturing sites of active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs) according to the Dutch Medicines Evaluation Board database (n = 407).**

Red = one manufacturing site for APIs and FPPs; orange = one manufacturing site for APIs or FPPs; green = at least two manufacturing sites for APIs and FPPs.

## Interdependency

The flow of the ten upstream pharmaceutical supply chains is illustrated in Sankey diagrams showing the journey from API manufacturer to FPP manufacturer, ending in an authorised medicinal product under the responsibility of an MAH (see supplementary figure S3). We identified two main patterns of supply chains, the 'isolated chain' and the 'intertwined chain', for example, as depicted in the diagrams of desloratadine (Figure 3A) and simvastatin (Figure 3B), respectively. The isolated chain involves (in extremis) one MAH depending on one API and one FPP manufacturer. The intertwined chain consists of multiple API and FPP manufacturers serving multiple MAHs.

Of the 70 distinct MAHs, 11 (16%) depended on one API manufacturer and one FPP site (isolated chain), 14 (20%) on one API manufacturer and multiple FPP sites, 20 (28%) on multiple API sites and one FPP manufacturer, and 25 (36%) on multiple API and FPP sites (intertwined chain). When an MAH relied on several manufacturers, the same combinations of API and FPP manufacturers (intertwined chain, Figure 3A and B) occurred.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

255                Simvastatin was remarkable because 29 of the 36 (81%) authorised medicinal products listed  
256 the same API manufacturer (Figure 3B; light blue). Upon closer examination, only nine of these  
257 products (25%) entirely depended on this manufacturer. A further analysis of the manufacturer  
258 dependencies for all substances showed that amoxicillin was notable for 50% of authorised products  
259 relying on one and the same API manufacturer, and omeprazole was notable for 46% of authorised  
260 products relying on one and the same FPP manufacturer (see supplementary table S2).

261  
262 **Figure 3: Exemplary supply chains for desloratadine (A) and simvastatin (B)**

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

## DISCUSSION

### Principal findings

This explorative study on supply chain vulnerabilities of ten high-use pharmaceuticals unravelled several overall existing concerns. For these substances, a significant proportion of the API and FPP manufacturing sites were located in Europe, and an even higher proportion of the related authorised medicinal products listed an API or FPP manufacturing site in Europe. All ten substances had a supplier base exceeding at least three different API and FPP manufacturers, which is desirable for a viable market [21]. Dual sourcing for API and FPP manufacturing, however, was present for a minority of the authorised medicinal products.

The dependency on API and FPP manufacturing sites in Asia [15, 16] was less pronounced than expected. For the ten substances, 43% and 74% of the API and FPP manufacturing sites, respectively, were located in Europe and were involved in the manufacturing of 68% and 84% of the related authorised medicinal products, respectively. However, for four pharmaceutical substances, more than half of the products (54–67%) did rely on non-European API manufacturers. For each pharmaceutical substance, at least four different API and seven different FPP manufacturers were listed, thus exceeding an supplier base of at least three manufacturers for APIs and FPPs. [21] Nevertheless, some substances were overdependent on one and the same manufacturer, such as amoxicillin (strongly depending on one and the same API manufacturer) and omeprazole (strongly depending on one and the same FPP manufacturer). MAHs had adopted a dual sourcing strategy for API and FPP manufacturing for only 15% of the authorised medicinal products. For three substances, none of the authorised products listed two or more manufacturing sites for the APIs and FPPs. This limited share of products with dual sourcing for APIs and FPPs and the overdependency on specific manufacturers were serious supply chain vulnerabilities observed in this study.

### Comparison with previous research

Studies on API and FPP manufacturers and their geographic locations have been limited. For the API market in general, we found data regarding the geographic distribution of manufacturers in relation to turnover according to suppliers. [18] Since the underlying numbers are lacking, the data are difficult to interpret. Recently, the European Commission published the results of the assessment of the supply chain vulnerabilities conducted in 2024 for a first tranche of 11 critical medicines from the Union list. [25] Using data collected from both EU member states and MAHs, several aspects were evaluated including diversification and geographic location of manufacturers. The risk thresholds/levels applied in this assessment (e.g. high risk with < 4 manufacturing sites), suggest that even more substances are at high risk compared to our findings. Similar to our study, this assessment found that MAHs were relatively less dependent on non-EU finished product manufacturers compared to their dependency on non-EU API manufacturers.

A recent study on generic APIs linked their manufacturing characteristics to medicine shortages in the U.S. [29]. This linkage provides an interesting possibility for further research.

### Strengths and limitations

The major strength of our study is that we could analyse API as well as FPP manufacturing sites, the responsible MAHs, and their interdependencies. Our study showed that an analysis of



1  
2  
3 303 geographic location of only manufacturing sites is limited, since the geographic distribution of  
4 304 manufacturing sites differed from the geographic distribution of the sites for the medicinal products.  
5  
6 305 Whereas 43% of the API manufacturing sites were located in Europe, 68% of the authorised medicinal  
7 306 products listed an API manufacturing site in Europe (36% in Europe only and 32% in Europe and  
8  
9 307 another continent). For FPP manufacturing, 74% of the sites were in Europe and 84% of the  
10 308 authorised medicinal products listed a site in Europe. Larger differences were observed at the  
11 309 individual product level. Our analysis also yielded insights into the implementation of dual sourcing for  
12 310 over 400 authorised medicinal products.

13  
14 311 Our study has three limitations. First, our cohort of ten high-use pharmaceutical substances  
15 312 out of over 13,000 (15) is unlikely to be representative of all medicines. For example, all of our  
16 313 substances are related to off-patent products. However, diverse supply chains were expected for high-  
17 314 use medicines because they are usually marketed by many MAHs. Also, the manufacturing of these  
18 315 off-patented medicines introduced complexity into the upstream supply chain due to increased  
19 316 outsourcing. (14) The overdependency on one and the same manufacturer, as observed for some  
20 317 substances in this study, is expected more often for other pharmaceutical substances, such as  
21 318 substances for niche medicines. For these ten substances, we also detected different patterns in the  
22 319 supply chains (isolated and intertwined supply chains), but we could not identify an overall sourcing  
23 320 strategy based on our data. Second, the included products were selected based on marketing  
24 321 authorisation in the Netherlands. Although MAHs may have different product portfolios in various  
25 322 countries, similar supply chain patterns are expected for products licenced in other countries in the EU  
26 323 or the European Economic Area (EEA), because most regulatory pathways in this region lead to  
27 324 authorisation in multiple member states or the entire EU or EEA. [36] Third, we focused only on API  
28 325 and FPP manufacturers and MAHs. Supply vulnerabilities can also be related to other factors, such as  
29 326 raw material and intermediate manufacturers, packaging sites, wholesalers, and distributors. The  
30 327 selected stakeholders are a crucial starting point, since they represent stringently regulated, core  
31 328 entities in the supply chain, and information on them could be extracted from a regulatory authority's  
32 329 database.

33  
34  
35  
36  
37  
38  
39  
40  
41  
42 330 **Implications for policymakers and clinicians**

43 331 Our granular analysis of the upstream pharmaceutical supply chains, displayed in Sankey  
44 332 diagrams, better facilitates the identification of supply chain vulnerabilities than numerical metrics. This  
45 333 facilitation will contribute to establishing effective measures to mitigate medicine shortages.

46 334 This study provides transparency in the API and FPP manufacturing and related MAHs of ten  
47 335 high-use pharmaceuticals. Although the information on authorised medicinal products and related  
48 336 MAHs was readily available in the public database of medicine agencies, the specific manufacturing  
49 337 sites were not disclosed. Product-specific information regarding supply chains is closely guarded by  
50 338 the MAHs as trade secrets or confidential commercial information. [37, 38] Even though authorities  
51 339 have access to information on the specific manufacturing sites, this information is not necessarily  
52 340 available in a format enabling automated processing. [20] More transparency and standardised data  
53 341 on the supply chain, such as information on the APIs and FPPs that manufacturers prefer [39], would

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

allow for an improved analysis of vulnerabilities by MAHs or authorities. Various stakeholders have advocated the need for further transparency [17, 20].

The EU is conducting an analysis of the supply chains for medicines on the EU list of critical medicines to identify vulnerabilities and to determine how these can best be addressed. [24] However, supply chains for pharmaceutical substances not included on the current EU list of critical medicines, also showed vulnerabilities, such as strong dependency on one and the same FPP manufacturer (omeprazole) and manufacturing sites mainly located outside Europe (simvastatin). Policymakers should not overlook substances that are not indicated as critical at a regional or national level since supply interruptions for non-critical substances may also have a considerable societal impact due to the significant number of patients affected. Our study showed that the supply chains for these ten substances may be vulnerable due to the lack of dual sourcing, and overdependency on a specific manufacturer.

In addition to transparency concerning API and FPP manufacturers and MAHs, an analysis of the relationship between supply chain vulnerabilities and the occurrence of medicine shortages in daily practice could provide further insights to help establish secure, resilient pharmaceutical supply chains.

## CONCLUSION

Our study on the supply chains of high-use generic pharmaceutical substances identified the need for a granular assessment of the interdependencies between API and FPP manufacturers and MAHs to identify upstream supply chain vulnerabilities.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ETHICS STATEMENTS**

**Ethics approval**

Not required, since this study did not involve human subjects and therefore ethical approval was not sought.

**Consent for publication**

Not applicable

**DATA AVAILABILITY STATEMENT**

No additional data available, since data is related manufacturing locations of specific medicinal products and manufacturers, which is confidential information.

Access to the internal database of the Dutch Medicines Evaluation Board (MEB) was granted to DJP as part of her joint PhD trajectory with involvement of the MEB, Royal Dutch Pharmacists Association (KNMP) and University Utrecht. Conflict of interest and a confidentiality agreement was signed by DJP. Data on individual authorised medicinal products, manufacturers and MAHs are published in a de-identified manner. The manuscript was checked by the legal department of the MEB for confidential information prior to publishing.

**ACKNOWLEDGMENTS**

The authors wish to thank the Dutch MEB for access to data in de MEB internal database and Rutger van den Broek (Dutch MEB) for retrieving the data from the internal database.

**FOOTNOTES**

**Contributors**

All authors conceived and designed the study. DJP performed the first analysis of the data and KN verified the study data. All authors contributed to the interpretation of the results. DJP and KN drafted the manuscript and prepared tables and figures. All authors read and critically reviewed and commented on each draft of the manuscript and approved the final manuscript for submission. DJP is the study guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

**Funding**

This work was supported by the Dutch Medicines Evaluation Board and the Royal Dutch Pharmacists Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interest statement**

All authors have completed the ICMJE uniform disclosure form at \_ and declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Disclaimer**

The views expressed in this article are the personal views of the authors and must not be understood or quoted as being made on behalf of or reflecting the position of the Dutch Medicines Evaluation Board or the Royal Dutch Pharmacists Association.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

### 399 **Transparency**

400 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and  
401 transparent account of the study being reported; that no important aspects of the study have been  
402 omitted; and that any discrepancies from the study as planned (and if relevant, registered) have been  
403 explained.

### 404 **Dissemination to participants and related patient and public communities**

405 The authors plan to actively disseminate the study findings to the public and patients through social  
406 media and plain-language summaries on the websites of the authors' affiliated organisations. Also, the  
407 study findings will be forwarded to organisations participating in the national Working group on  
408 medicine shortages coordinated by the ministry of health, with representatives of all relevant  
409 stakeholders such as pharmaceutical industry, health care professionals, patients and regulatory  
410 authorities.

REFERENCES

1. World Health Organization. Addressing the Global Shortage of Medicines and Vaccines. WHA Resolution. 2016. Sixty-ninth World Health Assembly, WHA69.25. Available from: <https://www.who.int/publications/i/item/wha-69.25>.

2. Huys I, Simoons S. European drug shortages: a call for action! *Int J Pharm Pract*. 2013;21(1):1-2.

3. Tucker EL, Cao Y, Fox ER, et al. The Drug Shortage Era: A Scoping Review of the Literature 2001–2019. *Clinical Pharmacology & Therapeutics*. 2020;108(6):1150-5.

4. European Medicines Agency, Heads of Medicines Agencies. Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders (MAHs) in the Union (EEA). 2019. Available from: [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-detection-notification-shortages-medicinal-products-marketing-authorisation-holders-mahs\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-detection-notification-shortages-medicinal-products-marketing-authorisation-holders-mahs_en.pdf).

5. Fink S. Drug Shortages Forcing Hard Decisions on Rationing Treatments. *The New York Times*. 2016 29 January, 2016.

6. Fox ER, Unguru Y. Oncology drug shortages in the USA — business as usual. *Nature Reviews Clinical Oncology*. 2020;17(3):128-9.

7. Dutch Medicines Evaluation Board. Meldpunt Geneesmiddelen tekorten en -defecten 2022 [Report on Medicine shortages and defects notification centre 2022]. 2023. Available from: <https://www.cbg-meb.nl/documenten/rapporten/2023/03/07/rapportage-meldpunt-geneesmiddelen-tekorten-en--defecten-2022>.

8. European Association of Hospital Pharmacists. 2019 EAHP Medicines shortages report. 2020. Available from: <https://www.eahp.eu/practice-and-policy/medicines-shortages/2019-medicines-shortage-survey>.

9. Robinson JC. Organizational economics and health care markets. *Health Serv Res*. 2001;36(1 Pt 2):177-89.

10. Choo EK, Rajkumar SV. Medication Shortages During the COVID-19 Crisis: What We Must Do. *Mayo Clin Proc*. 2020;95(6):1112-5.

11. Cameron EE, Bushell MA. Analysis of drug shortages across two countries during pre-pandemic and pandemic times. *Research in social & administrative pharmacy : RSAP*. 2021;17(9):1570-3.

12. Vogler S. Tackling medicine shortages during and after the COVID-19 pandemic: Compilation of governmental policy measures and developments in 38 countries. *Health Policy*. 2024;105030.

13. Chapman S, Dedet G, Lopert R. Shortages of medicines in OECD countries. 2022. Available from: <https://www.oecd-ilibrary.org/content/paper/b5d9e15d-en>.

14. Wagner SM, Grosse-Ruyken PT, Erhun F. Determinants of sourcing flexibility and its impact on performance. *International Journal of Production Economics*. 2018;205:329-41.

15. Gibson R. Exploring the Growing U.S. Reliance on China's Biotech and Pharmaceutical Products. 2019. Available from: <https://www.uscc.gov/sites/default/files/RosemaryGibsonTestimonyUSCCJuly152019.pdf>.

16. European Parliament. Shortage of medicines - how to deal with an emerging problem. 2020. Available from: [https://www.europarl.europa.eu/doceo/document/TA-9-2020-0228\\_EN.html](https://www.europarl.europa.eu/doceo/document/TA-9-2020-0228_EN.html).

17. European Medicines Agency, Heads of Medicines Agencies. European medicines agencies network strategy to 2025. 2020. Available from:

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- <https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network/european-medicines-agencies-network-strategy>.
18. European Fine Chemicals Group. APIs Facts & Figures. 2022. Available from: [https://efcg.cefic.org/wp-content/uploads/2022/11/EFCG-2\\_Aug-APIs-FactsFigures-1.pdf](https://efcg.cefic.org/wp-content/uploads/2022/11/EFCG-2_Aug-APIs-FactsFigures-1.pdf).
19. European Medicines Agency, Heads of Medicines Agencies. Good practices for industry for the prevention of human medicinal product shortages. 2024. Available from: [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages_en.pdf).
20. European Commission. Vulnerabilities of the global supply chains of medicines - Structured Dialogue on the security of medicines supply. 2023. Available from: [https://health.ec.europa.eu/latest-updates/staff-working-document-vulnerabilities-global-supply-chains-medicines-structured-dialogue-security-2022-10-17\\_en](https://health.ec.europa.eu/latest-updates/staff-working-document-vulnerabilities-global-supply-chains-medicines-structured-dialogue-security-2022-10-17_en).
21. Hedman L. Medicines shortages: global approaches to addressing shortages of essential medicines in health systems. WHO Drug Information. 2016;30(2):180-5.
22. European Commission: Directorate-General for Health and Food Safety, Jongh T, Becker D, et al. Future-proofing pharmaceutical legislation - Study on medicine shortages - Executive summary. 2021. Available from: <https://data.europa.eu/doi/10.2875/236176>.
23. Food and Drug Administration. Executive Order 14017 on America's Supply Chains. 2024. Available from: <https://www.fda.gov/about-fda/reports/executive-order-14017-america-supply-chains>.
24. European Medicines Agency. Availability of critical medicines. 2023. Available from: <https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues/availability-medicines-during-crises#union-list-of-critical-medicines-64278>.
25. European Commission. Assessment of the supply chain vulnerabilities for the first tranche of the Union list of critical medicines: technical report. 2024. Available from: [https://health.ec.europa.eu/publications/assessment-supply-chain-vulnerabilities-first-tranche-union-list-critical-medicines-technical-report\\_en](https://health.ec.europa.eu/publications/assessment-supply-chain-vulnerabilities-first-tranche-union-list-critical-medicines-technical-report_en).
26. Tucker EL, Daskin MS. Pharmaceutical supply chain reliability and effects on drug shortages. Computers & Industrial Engineering. 2022;169:108258.
27. Tucker EL, Daskin MS, Sweet BV, et al. Incentivizing resilient supply chain design to prevent drug shortages: policy analysis using two- and multi-stage stochastic programs. IIE Transactions. 2020;52(4):394-412.
28. Doroudi R, Azghandi R, Feric Z, et al. An integrated simulation framework for examining resiliency in pharmaceutical supply chains considering human behaviors. 2018 Winter Simulation Conference (WSC); 2018 9-12 Dec. 2018.
29. Socal MP, Crane MA, Anderson GF. Global Production of Active Pharmaceutical Ingredients for US Generic Drugs Experiencing Shortages. JAMA. 2024;331(20):1763-5.
30. Postma DJ, De Smet PAGM, Notenboom K, et al. Impact of medicine shortages on patients - a framework and application in the Netherlands. BMC health services research. 2022;22(1):1366.
31. Dutch Foundation for Pharmaceutical Statistics. Laxeermiddel macrogol telt meeste gebruikers in 2021 [Laxative macrogol has most users in 2021]. 2022. Available from: <https://www.sfk.nl/publicaties/PW/2022/laxeermiddel-macrogol-telt-meeste-gebruikers-in-2021>.
32. Dutch Foundation for Pharmaceutical Statistics. Personal Communication. 2023.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

33. WHO Collaborating Centre for Drug Statistics Methodology. ATC - Structure and principles. 2022. Available from: [https://www.whocc.no/atc/structure\\_and\\_principles/](https://www.whocc.no/atc/structure_and_principles/).

34. Dutch Medicines Evaluation Board. Medicines Information Bank. 2024. Available from: <https://www.geneesmiddeleninformatiebank.nl>.

35. Socal MP, Ahn K, Greene JA, et al. Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients. Health Aff (Millwood). 2023;42(3):407-15.


36. Heads of Medicines Agencies. Medicines Approval System. Available from: <https://www.hma.eu/about-hma/medicines-approval-system.html>.

37. Norwegian Directorate of Health. Meeting Report Antibiotic Shortages: Magnitude, Causes and Possible Solutions on 10-11 December 2018. Geneva, World Health Organization; 2019.; 2019. Report No.: WHO/MVP/EMP/IAU/2019.02.

38. Drug Shortages Task Force. Drug Shortages: Root Causes and Potential Solutions. 2019. Available from: <https://www.fda.gov/media/131130/download>.


39. USP. Medicines Supply Map. Available from: <https://www.usp.org/supply-chain/medicine-supply-map>.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).



Selection of pharmaceutical substances with the largest number of patients in the Dutch outpatient setting and the related authorised medicinal products for analysis


190x254mm (96 x 96 DPI)



Number of authorised medicinal products with the corresponding number of manufacturing sites of active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs) according to the Dutch Medicines Evaluation Board database (n = 407).  
Red = one manufacturing site for APIs and FPPs; orange = one manufacturing site for APIs or FPPs; green = at least two manufacturing sites for APIs and FPPs.

645x645mm (600 x 600 DPI)





Exemplary supply chains for desloratadine (A) and simvastatin (B)

172x175mm (600 x 600 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**SUPPLEMENT TABLES AND FIGURES**

**Supply chain vulnerabilities of high-use pharmaceuticals: an explorative cohort study**

Doerine J Postma, Peter AGM De Smet, Aukje K Mantel-Teeuwisse, Hubert GM Leufkens, Kim Notenboom

**Table S1** – Overview of the included authorised medicinal products for outpatient use (n=407)


**Table S2** – Authorised medicinal products relying on one (and the same) API or FPP manufacturer

**Figure S1** – Number of authorised medicinal products with a manufacturing site per country - active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP)\*

**Figure S2** – Number of manufacturing sites per authorised medicinal product - active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP)

**Figure S3** – Supply chains per pharmaceutical substance

**FIGURE S1 – NUMBER OF AUTHORISED MEDICINAL PRODUCTS WITH A MANUFACTURING SITE PER COUNTRY - ACTIVE PHARMACEUTICAL INGREDIENT (API) AND FINISHED PHARMACEUTICAL PRODUCT (FPP)\***



\* the sum of the products may be higher than the total number of products since a regulatory dossier for an authorised medicinal product may list manufacturers located in different countries

**FIGURE S2 – NUMBER OF MANUFACTURING SITES PER AUTHORISED MEDICINAL PRODUCT - ACTIVE PHARMACEUTICAL INGREDIENT (API) AND FINISHED PHARMACEUTICAL PRODUCT (FPP)**









FIGURE S3 – SUPPLY CHAINS PER PHARMACEUTICAL SUBSTANCE






Enseignement Supérieur (ABES) : Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.







Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**TABLE S1 – OVERVIEW OF THE INCLUDED AUTHORISED MEDICINAL PRODUCTS FOR OUTPATIENT USE (N=407)**

pharmaceutical substance	ATC 5th level code	therapeutic use	number of patients (% of population)	patented or off-patent	number of authorised medicinal products				number of marketing authorisation holders (MAHs)
					total	oral	inhalable	rectal	
amoxicillin	J01CA04	bacterial infection	815,000 (4.7)	off-patent	32	32			9
colecalfiferol	A11CC05	vitamin D deficiency	1,005,000 (5.8)	off-patent	82	82			24
desloratadine	R06AX27	allergy	740,000 (4.3)	off-patent	34	34			17
diclofenac	M01AB05	pain	815,000 (4.7)	off-patent	29	21		8	11
levonorgestrel/ ethinylestradiol	G03AA07	contraception	1,000,000 (5.7)	off-patent	21	21			10
metoprolol	C07AB02	high blood pressure	1,010,000 (5.8)	off-patent	34	34			10
omeprazole	A02BC01	(prevention of) stomach ache	1,290,000 (7.4)	off-patent	85	85			19
pantoprazole	A02BC02	(prevention of) stomach ache	1,285,000 (7.4)	off-patent	33	33			15
salbutamol	R03AC02	asthma and COPD	780,000 (4.5)	off-patent	21		21		8
simvastatin	C10AA01	high cholesterol	845,000 (4.8)	off-patent	36	36			10
<b>Total</b>			<b>6,475,000* (37)</b>		<b>407</b>	<b>378</b>		<b>8</b>	<b>70**</b>

\* The total (unique) number of patients is lower than the sum of the number of patients since nearly half of patients used more than one pharmaceutical substance.

\*\*The total number of MAHs is lower than the sum of the MAHs since one MAH can market authorised medicinal products for different substances.



TABLE S2 – AUTHORISED MEDICINAL PRODUCTS RELYING ON ONE (AND THE SAME) API OR FPP MANUFACTURER

A. Active pharmaceutical ingredient (API) manufacturer

pharmaceutical substance	number of authorised medicinal products		
	total	one API manufacturer	one and the same API manufacturer
amoxicillin	32	24 (75%)	16 (50%)
colecalfiferol	82	64 (78%)	34 (41%)
desloratadine	34	11 (32%)	3 (9%)
diclofenac	29	20 (69%)	12 (41%)
levonorgestrel / ethinylestradiol	21	15 (71%)	7 (33%)
metoprolol	34	10 (48%)	10 (48%)
omeprazole	34	12 (35%)	8 (24%)
omeprazole	85	20 (24%)	8 (9%)
pantoprazole	33	3 (9%)	2 (6%)
salbutamol	21	8 (38%)	1 (5%)
simvastatin	36	9 (25%)	9 (25%)

B. Finished pharmaceutical product (FPP) manufacturer

pharmaceutical substance	number of authorised medicinal products		
	total	one FPP manufacturer	one and the same FPP manufacturer
amoxicillin	32	17 (53%)	6 (19%)
colecalfiferol	82	44 (54%)	7 (9%)
desloratadine	34	29 (85%)	6 (7%)
diclofenac	29	15 (52%)	4 (14%)
levonorgestrel / ethinylestradiol	21	20 (95%)	8 (38%)
metoprolol	34	22 (65%)	9 (26%)
omeprazole	85	82 (86%)	39 (46%)
pantoprazole	33	11 (31%)	5 (14%)
salbutamol	21	18 (86%)	5 (24%)
simvastatin	36	5 (31%)	3 (8%)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

# BMJ Open

## Upstream pharmaceutical supply chains of ten high-use pharmaceuticals in the Netherlands: a cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2025-099697.R1
Article Type:	Original research
Date Submitted by the Author:	19-Mar-2025
Complete List of Authors:	Postma, Doerine; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology; Royal Dutch Association for the Advancement of Pharmacy De Smet, Peter AGM; Radboud University, Departments of Clinical Pharmacy and IQ Healthcare, Institute for Health Sciences Mantel-Teeuwisse, Aukje; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology Leufkens, Hubert; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology & Clinical Pharmacology Notenboom, Kim; Medicines Evaluation Board
<b>Primary Subject Heading</b>:	Health policy
Secondary Subject Heading:	Health policy, Public health
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH, Pharmacists, Medicine

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



*I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).*

*The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.*

*Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.*

<b>Title</b>	Upstream pharmaceutical supply chains of ten high-use pharmaceuticals in the Netherlands: a cohort study
<b>Authors' names</b>	Doerine J Postma (0000-0001-7129-1624), Peter AGM De Smet (0000-0003-1762-6547), Aukje K Mantel-Teeuwisse (0000-0002-8782-0698), Hubert GM Leufkens (0000-0002-7175-1499), Kim Notenboom (0009-0007-2795-134X)
<b>Authors names and positions</b> <b>Address for each author</b>	<p><b>Doerine J Postma</b>, researcher, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Peter AGM De Smet</b>, emeritus professor of pharmaceutical care, Departments of Clinical Pharmacy and IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, the Netherlands</p> <p><b>Aukje K Mantel-Teeuwisse</b>, professor of pharmacy and global health, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Hubert GM Leufkens</b>, emeritus professor of pharmaceutical policy and regulation, Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands</p> <p><b>Kim Notenboom</b>, research associate, Medicines Evaluation Board, PO Box 8275, 3503 RG Utrecht, the Netherlands</p>
<b>Corresponding author</b>	Correspondence to: a.k.mantel@uu.nl. Aukje K Mantel-Teeuwisse, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands, (0031)30 253 7324

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

**UPSTREAM PHARMACEUTICAL SUPPLY CHAINS OF TEN HIGH-USE PHARMACEUTICALS IN THE NETHERLANDS: A COHORT STUDY**

*Doerine J Postma,<sup>1,2</sup> Peter AGM De Smet,<sup>3</sup> Aukje K Mantel-Teeuwisse,<sup>\*1</sup> Hubert GM Leufkens,<sup>1</sup> Kim Notenboom<sup>4</sup>*

1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

2. Royal Dutch Pharmacists Association, The Hague, the Netherlands

3. Radboud University Medical Centre, Radboud Institute for Health Sciences, Departments of IQ Healthcare and Clinical Pharmacy, Nijmegen, the Netherlands

4. Dutch Medicines Evaluation Board, Utrecht, the Netherlands

<sup>\*</sup>Corresponding author: Aukje K Mantel-Teeuwisse | Universiteitsweg 99, 3584 CG Utrecht, The Netherlands, a.k.mantel@uu.nl, (0031)30 253 7324

**ABSTRACT**

**Objectives** – To assess the upstream pharmaceutical supply chains of ten high-use pharmaceuticals to detect vulnerabilities that may increase the risk of medicine shortages

**Design** – Cohort study

**Setting** – Dutch outpatient setting in 2022

**Participants** – A total of 407 authorised medicinal products for ten pharmaceutical substances with the largest number of outpatients

**Main outcome measures** – The diversity of active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP) manufacturers, their geographic locations and the interdependencies between these manufacturers and marketing authorisation holders (MAHs)

**Results** – For the 407 authorised medicinal products, 50 of the 90 API manufacturing sites were in Asia, and 38 in Europe. For five pharmaceutical substances, most of the API sites were located outside Europe. Of the 128 FPP manufacturing sites, 94 were in Europe, and 31 in Asia. For all ten substances, at least 47% of FPP sites were located in Europe.

API manufacturing for 122 of the 407 products (30%) was entirely performed outside Europe, and FPP manufacturing for 66 of the 407 products (16%). For four substances, more than half of the products depended on API manufacturing outside Europe.

The number of distinct API and FPP manufacturing sites per substance was at least four. For amoxicillin, 16 of the 32 products (50%) entirely depended on one and the same API site. For omeprazole, 39 of the 85 products (46%) entirely depended on one and the same FPP site.

MAHs applied dual sourcing for API and FPP manufacturing for 61 (15%) of the authorised medicinal products. For three pharmaceutical substances, none of the authorised medicinal products listed at least two API and FPP manufacturing sites.

**Conclusion** – Our study of the supply chains of high-use pharmaceutical substances indicates the need for a granular assessment of the interdependencies between MAHs, API and FPP manufacturers to identify upstream supply chain vulnerabilities.

## STRENGTHS AND LIMITATIONS

- This study offers insights into the pharmaceutical supply chains, focussing on the diversity of API and FPP manufacturers and their geographic locations.
- The use of Dutch Medicines Evaluation Board database to analyse the research question is ideal since this is the official source to register this information.
- We visualised the ten upstream pharmaceutical supply chains using Sankey diagrams, illustrating the complex interdependencies among stakeholders.
- Our cohort of ten pharmaceutical substances is unlikely to be representative of all medicines.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

52   **INTRODUCTION**

53           A continuous supply of quality-assured, safe, effective, and affordable medicines is essential

54   for a well-functioning health system. [1] Until the beginning of the 21<sup>st</sup> century the availability of

55   medicines did not significantly concern high-income countries. Then, discrepancies between supply

56   and demand began to frequently emerge. [2-4] Currently, medicine shortages are ‘the new normal’. [5,

57   6] The main causes of medicine shortages are related to manufacturing and quality issues [7, 8],

58   which are part of the upstream supply chain, from active pharmaceutical ingredient (API) to FPP

59   manufacturing and packaging, rather than the downstream distribution. [9] Despite the increased focus

60   on the availability of medicines during the COVID-19 pandemic, shortages further increased post-

61   COVID-19, [10-12] underscoring the necessity of addressing the ongoing challenges in the

62   pharmaceutical supply chain.

63           The pharmaceutical supply chain is complex, involving multiple interdependent stakeholders

64   and relying on a global distribution network. MAHs are responsible for their authorised medicinal

65   products and for the qualification and selection of the involved (number of) manufacturers. MAHs often

66   rely on manufacturers located worldwide to produce APIs and finished pharmaceutical products

67   (FPPs). [13] MAHs may decide to manufacture APIs and FPPs in-house, which offers control over

68   quality, quantity, and timelines, thus providing the flexibility to rapidly respond to manufacturing

69   problems requiring expertise and resources. However, manufacturing generic products is increasingly

70   outsourced, enlarging external dependency and introducing complexity into the upstream supply

71   chain. [14] A much-raised additional concern is the geographical location and concentration of

72   manufacturing sites, particularly in Asia. [15-17] Studies on manufacturing sites and their geographic

73   locations are limited. For the API market in general, we found data regarding the geographic

74   distribution of manufacturers in relation to turnover. According to the researchers, API manufacturing

75   for the European market is predominantly situated in Asia (56%), followed by Western Europe (24%)

76   and North America (12%), with limited contributions from the rest of the world (8%). [18]

77           The supply chain may be disturbed by manufacturing issues, natural disasters, or geopolitical

78   disputes. Problems with API availability may disrupt FPP manufacturing, impact the marketing of

79   authorised medicinal products by MAHs, prohibit dispensing by the pharmacist, and ultimately restrict

80   patient access. A robust supply chain would prevent a problem occurring at one point in the supply

81   from causing disruptions elsewhere. To enhance supply chain resilience, ensuring supplier diversity is

82   considered crucial. [19, 20] For a viable market, a supplier base of at least three different API and FPP

83   manufacturers per pharmaceutical substance is considered desirable according to participants at a

84   WHO-convened technical consultation. [21] Dual sourcing strategies per authorised medicinal product

85   – establishing two suppliers for a given ingredient or component in a regulatory product dossier – is

86   also a well-known measure. [20, 22]

87           Supply chain resilience is in the spotlight of global pharmaceutical policies. [17, 23] The

88   European Commission is analysing supply chains of medicines on the EU list of critical medicines to

89   identify vulnerabilities. Foreseen EU policy measures to strengthen these supply chains include

90   regulatory flexibilities and recommendations to diversify manufacturers and increase Europe’s

91   manufacturing capacity. [24-26] Insight into interdependencies among stakeholders – such as the

number of API manufacturers supplying FPP manufacturers and the subsequent number of FPP manufacturers supplying different MAHs, along with their geographic locations – can help to identify supply chain vulnerabilities. Although geographic concentration is often reported as an issue, and medicine shortages and pharmaceutical supply chain vulnerabilities have been linked by some researchers [27-30], no studies have specifically analysed the interdependencies among stakeholders in the upstream pharmaceutical supply chain. There is currently also no method that could be translated into public health resilience planning.

This research aimed to assess pharmaceutical supply chains by evaluating the diversity of API and FPP manufacturers, their geographic locations and the interdependencies between MAHs and these manufacturers. We selected ten pharmaceutical substances with the largest number of outpatients in the Netherlands since supply disruptions of these medicines may affect a significant share of the population.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**METHODS**

**Study population and data collection**

For this cohort study, ten pharmaceutical substances with the largest number of patients in the Dutch outpatient setting were chosen because the number of patients is a key element determining a shortage’s impact. [31] As a result of choosing the number of patients (instead of for example the total annual volume) all treatments were counted equally, regardless of treatment duration. The ten high-use pharmaceutical substances in 2021 originated from the database of the Dutch Foundation for Pharmaceutical Statistics [32, 33], which contains complete information on the Dutch outpatient setting including the outpatient pharmacies in hospitals. The pharmaceutical substances were classified according to the WHO’s Anatomical Therapeutic Chemical (ATC) classification system, which classifies active pharmaceutical substances into five hierarchical levels according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. ATC on the fifth level indicates the active substance, also known as API. [34] We included pharmaceutical substances containing one or a fixed combination of two active components.

The medicinal products containing these ten pharmaceutical substances authorised in the Netherlands, along with their responsible MAHs and the involved API and FPP manufacturers and their geographic locations, were identified using the Dutch Medicines Evaluation Board (MEB) [35] database in July 2022. We excluded products for parenteral use such as solution for injection or infusion. These products are mainly prescribed in hospital settings and therefore not included in the data from the Dutch Foundation for Pharmaceutical Statistics.

**Study outcomes and data analysis**

For the authorised medicinal products, a researcher (DJP) obtained distinct MAHs, API and FPP manufacturers, and geographic locations of the manufacturers at the country and continent levels. The geographic locations were limited to API and FPP manufacturing sites because they are more geographically bound than MAHs, and regulatory requirements are involved when changing them. [36]

We calculated the median number of authorised medicinal products per MAH and the interquartile range (IQR) and range. For authorised medicinal products, we plotted the number of API versus FPP manufacturing sites on a bubble chart. For products containing two pharmaceutical substances, we only plotted the manufacturers of the substances with the fewest API manufacturers because it represented the worst case and, thus, greatest overall vulnerability.

We mapped the pharmaceutical supply chains using Sankey diagrams containing nodes and links to visualise stakeholder interdependencies. The nodes represent the API manufacturer, the FPP manufacturer, authorised medicinal products, and the MAH, respectively. The links show their interactions. The width of the nodes is proportional to the number of links; a wider node means more interaction with next-stage stakeholders.

Descriptive statistics present the characteristics of authorised medicinal products and manufacturing sites. Graphics were created using Microsoft Office 365 Excel and Adobe Illustrator (Sankey diagrams).

1  
2  
3 143 **Patient and Public Involvement**

4 144 Neither patients nor the public were involved in the conception, design, or execution of this study.

6 145 **ETHICS STATEMENTS**

8 146 **Ethics approval**

9 147 Ethics approval was not required according to Dutch law, since this study did not involve human  
11 148 subjects.

12 149 **Consent for publication**

14 150 Not applicable

15 151

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**RESULTS**

The ten pharmaceutical substances with the largest number of patients in the outpatient setting in the Netherlands included two ATC fifth-level substances containing more than two active components. These two substances were replaced by the next two ATC fifth-level substances that met the inclusion criteria. For the selected substances, 407 medicinal products for outpatient use were authorised in the Netherlands in July 2022 (Figure 1). In total, 37% of the Dutch population (6.5 million people) received a prescription for one or more of the selected medicinal products (see supplementary table S1).

**Figure 1: Selection of pharmaceutical substances with the largest number of patients in the Dutch outpatient setting and the related authorised medicinal products for analysis**

The 407 products included authorised off-patent medicinal products predominantly intended for oral use (378; 93%), with a few for inhalation (21; 5%) or rectal use (8; 2%). The number of authorised medicinal products per pharmaceutical substance ranged from 21 for levonorgestrel/ethinylestradiol and salbutamol to 85 products for omeprazole. The 407 authorised medicinal products were the responsibility of 70 distinct MAHs (see supplementary table S1), and their manufacturing involved 90 distinct API sites and 128 distinct FPP sites. Three manufacturing sites produced APIs as well as FPPs. In our cohort of 407 products, the 70 MAHs were responsible for a median of three (IQR: 2–6) authorised medicinal products (range: 1–42). Of the 70 MAHs, 49 had marketing authorisations for products for one of the ten pharmaceutical substances. Three MAHs had marketing authorisations for products for nine of the ten pharmaceutical substances.

**API manufacturing**

The 90 API manufacturers for the 407 authorised medicinal products were mostly located in Asia (50; 55%), a large minority in Europe (38; 42%), and rarely in the Americas (2; 3%) (see Table 1 and supplementary figure S1). The number of distinct API manufacturing sites per pharmaceutical substance ranged from four for levonorgestrel/ethinylestradiol to 17 for pantoprazole. For desloratadine, diclofenac, metoprolol, pantoprazole, and simvastatin, more than half of the API manufacturing sites were located outside Europe (54%–82%). For amoxicillin and omeprazole, the API sites were equally divided outside and within Europe. For the remaining three substances, a minority of the sites were located outside Europe (range: 0%–40%) thus for the majority within Europe (60–100%). For all pharmaceutical substances at least two API manufacturing sites were located in Europe.

Among the 407 authorised medicinal products, 122 entirely relied on APIs manufactured outside of Europe (Table 1). For four substances (desloratadine, diclofenac, pantoprazole, and simvastatin), the authorised medicinal products predominantly relied on only API manufacturing sites outside of Europe (range: 52–66%). For colecalciferol, metoprolol and omeprazole, the API manufacturing sites were outside and within Europe. For the remaining three substances, the minority of the products relied on API sites outside Europe (range: 0–25%). The number of authorised

medicinal products per substance specified per country of the manufacturing site is displayed in supplementary figure S1.

**Table 1: Number and geographic location (continent) of active pharmaceutical ingredient (API) manufacturing sites and related medicinal products**

pharmaceutical substance	number of API manufacturing sites per continent			number of related authorised medicinal products per continent			
	total	Europe	other continents	total	Europe	Europe and other continents*	other continents
overall	90	38 (42%)	52 (58%)	407	146 (36%)	139 (34%)	122 (30%)
amoxicillin	6	3 (50%)	3 (50%)	32	24 (75%)		8 (25%)
colecalfiferol	5	3 (60%)	2 (40%)	82	47 (57%)	18 (22%)	17 (21%)
desloratadine	15	3 (20%)	12 (80%)	34		15 (44%)	19 (56%)
diclofenac	8	3 (38%)	5 (62%)	29	7 (24%)	3 (10%)	19 (66%)
levonorgestrel / ethinylestradiol	4	4 (100%)		21	21 (100%)		
metoprolol	13	6 (46%)	7 (54%)	34	13 (38%)	16 (47%)	5 (15%)
omeprazole	12	6 (50%)	6 (50%)	85	14 (16%)	56 (66%)	15 (18%)
pantoprazole	17	4 (24%)	13 (76%)	33		16 (48%)	17 (52%)
salbutamol	6	5 (83%)	1 (17%)	21	20 (95%)		1 (5%)
simvastatin	11	2 (18%)	9 (82%)	36		15 (42%)	21 (58%)

\* The regulatory dossier for an authorised medicinal product may list several API manufacturers on different continents.

### FPP manufacturing

The 128 FPP manufacturing sites for the 407 authorised medicinal products were mainly situated in Europe (94; 74%), to a lesser extent in Asia (31; 24%), and rarely in the Americas (3; 2%) (see Table 2 and supplementary figure S1). The number of distinct FPP manufacturing sites per pharmaceutical substance ranged from seven for levonorgestrel/ethinylestradiol to 23 for simvastatin. For pantoprazole a small majority (53%) of FPP sites were located outside Europe and for amoxicillin the FPP sites were equally divided outside and within Europe. For the other eight substances, the minority of FPP sites were located outside Europe (range: 0–48%). For all ten pharmaceutical substances at least five FPP manufacturing sites were present in Europe.

Of the related authorised medicinal products, 66 of the 407 (16%) were entirely manufactured outside Europe (Table 2). For all substances, the minority of the authorised medicinal products relied solely on FPP manufacturing outside Europe (range: 0–38%). The number of authorised medicinal products per substance specified per country of the manufacturing site is displayed in supplementary figure S1.

**Table 2: Number and geographic location (continent) of finished pharmaceutical product (FPP) manufacturing sites and related medicinal products**

pharmaceutical substance	Number of FPP manufacturing sites per continent			Number of related authorised medicinal products per continent			
	Total	Europe	other continents	total	Europe	Europe and other continents*	other continents
overall	128	94 (73%)	34 (17%)	407	286 (70%)	55 (14%)	66 (16%)

amoxicillin	10	5 (50%)	5 (50%)	32	23 (72%)		9 (28%)
colecalfiferol	21	17 (81%)	4 (19%)	82	56 (68%)	14 (17%)	12 (15%)
desloratadine	21	15 (71%)	6 (29%)	34	20 (59%)	1 (3%)	13 (38%)
diclofenac	19	16 (84%)	3 (16%)	29	24 (83%)	3 (10%)	2 (7%)
levonorgestrel/ ethinylestradiol	7	6 (86%)	1 (14%)	21	18 (86%)		3 (14%)
metoprolol	18	14 (78%)	4 (22%)	34	25 (74%)	5 (15%)	4 (12%)
omeprazole	10	7 (70%)	3 (30%)	85	77 (91%)	3 (3%)	5 (6%)
pantoprazole	17	8 (47%)	9 (53%)	33	14 (42%)	14 (42%)	5 (16%)
salbutamol	11	11 (100%)		21	21 (100%)		
simvastatin	23	12 (52%)	11 (48%)	36	8 (22%)	15 (42%)	13 (36%)

\* The regulatory dossier for an authorised medicinal product may list several FPP manufacturers on different continents.

Diversity of manufacturers

The regulatory dossiers of 346 of the 407 products (85%) listed either one API manufacturing and multiple FPP sites (83; 20%), one FPP manufacturing and multiple API sites (157; 39%), or one API and one FPP site (106; 26%) (Figure 2). For 61 authorised medicinal products (15%), at least two API and FPP sites were listed. For four substances, most authorised medicinal products (69%–78%) relied on one API manufacturing site. For eight substances, more than half of the authorised medicinal products (52%–95%) relied on one FPP manufacturing site (see supplementary table S2). For amoxicillin, colecalfiferol, and levonorgestrel/ethinylestradiol, none of the authorised products listed two or more manufacturing sites for the APIs and FPPs (see supplementary figure S2). For simvastatin and pantoprazole, most of the authorised medicinal products (both 61%) listed at least two manufacturing sites for the APIs and FPPs.

Figure 2: Number of authorised medicinal products with the corresponding number of manufacturing sites of active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs) according to the Dutch Medicines Evaluation Board database (n = 407).

Red = one manufacturing site for APIs and FPPs; orange = one manufacturing site for APIs or FPPs; green = at least two manufacturing sites for APIs and FPPs.

Interdependency

The flow of the ten upstream pharmaceutical supply chains is illustrated in Sankey diagrams showing the journey from API manufacturer to FPP manufacturer, ending in an authorised medicinal product under the responsibility of an MAH (see supplementary figure S3). We identified two main patterns of supply chains, the ‘isolated chain’ and the ‘intertwined chain’, for example, as depicted in the diagrams of desloratadine (Figure 3A) and simvastatin (Figure 3B), respectively. The isolated chain involves (in extremis) one MAH depending on one API and one FPP manufacturer. The intertwined chain consists of multiple API and FPP manufacturers serving multiple MAHs.

Of the 70 distinct MAHs, 11 (16%) depended on one API manufacturer and one FPP site (isolated chain), 14 (20%) on one API manufacturer and multiple FPP sites, 20 (28%) on multiple API sites and one FPP manufacturer, and 25 (36%) on multiple API and FPP sites (intertwined chain). When an MAH relied on several manufacturers, the same combinations of API and FPP manufacturers (intertwined chain, Figure 3A and B) occurred.

Simvastatin was remarkable because 29 of the 36 (81%) authorised medicinal products listed the same API manufacturer (Figure 3B; light blue). Upon closer examination, only nine of these products (25%) entirely depended on this manufacturer. A further analysis of the manufacturer dependencies for all substances showed that amoxicillin was notable for 50% of authorised products relying on one and the same API manufacturer, and omeprazole was notable for 46% of authorised products relying on one and the same FPP manufacturer (see supplementary table S2).

**Figure 3: Exemplary supply chains for desloratadine (A) and simvastatin (B)**

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**DISCUSSION**

**Principal findings**

This study on the upstream pharmaceutical supply chains of ten high-use pharmaceuticals unravelled several overall existing concerns. For these substances, a significant proportion of the API and FPP manufacturing sites were located in Europe, and an even higher proportion of the related authorised medicinal products listed an API or FPP manufacturing site in Europe. All ten substances had a supplier base exceeding at least three different API and FPP manufacturers, which is desirable for a viable market [21]. Dual sourcing for API and FPP manufacturing, however, was present for a minority of the authorised medicinal products.

The dependency on API and FPP manufacturing sites in Asia [15, 16] was less pronounced than expected. For the ten substances, 43% and 74% of the API and FPP manufacturing sites, respectively, were located in Europe and were involved in the manufacturing of 68% and 84% of the related authorised medicinal products, respectively. However, for four pharmaceutical substances, more than half of the products (54–67%) did rely on non-European API manufacturers. For each pharmaceutical substance, at least four different API and seven different FPP manufacturers were listed, thus exceeding an supplier base of at least three manufacturers for APIs and FPPs. [21] Nevertheless, some substances were overdependent on one and the same manufacturer, such as amoxicillin (strongly depending on one and the same API manufacturer) and omeprazole (strongly depending on one and the same FPP manufacturer). MAHs had adopted a dual sourcing strategy for API and FPP manufacturing for only 15% of the authorised medicinal products. For three substances, none of the authorised products listed two or more manufacturing sites for the APIs and FPPs. This limited share of products with dual sourcing for APIs and FPPs and the overdependency on specific manufacturers were serious supply chain vulnerabilities observed in this study.

**Comparison with previous research**

Studies on API and FPP manufacturers and their geographic locations have been limited. For the API market in general, we found data regarding the geographic distribution of manufacturers in relation to turnover according to suppliers. [18] Since the underlying numbers are lacking, the data are difficult to interpret. Recently, the European Commission published the results of the assessment of the supply chain vulnerabilities conducted in 2024 for a first tranche of 11 critical medicines from the Union list. [25] Using data collected from both EU member states and MAHs, several aspects were evaluated including diversification and geographic location of manufacturers. The risk thresholds/levels applied in this assessment (e.g. high risk with < 4 manufacturing sites), suggest that even more substances are at high risk compared to our findings. Similar to our study, this assessment found that MAHs were relatively less dependent on non-EU finished product manufacturers compared to their dependency on non-EU API manufacturers.

A recent study on generic APIs linked their manufacturing characteristics to medicine shortages in the U.S. [30]. This linkage provides an interesting possibility for further research.

**Strengths and limitations**

The major strength of our study is that we could analyse API as well as FPP manufacturing sites, the responsible MAHs, and their interdependencies. Our study showed that an analysis of

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

geographic location of only manufacturing sites is limited, since the geographic distribution of manufacturing sites differed from the geographic distribution of the sites for the medicinal products. Whereas 43% of the API manufacturing sites were located in Europe, 68% of the authorised medicinal products listed an API manufacturing site in Europe (36% in Europe only and 32% in Europe and another continent). For FPP manufacturing, 74% of the sites were in Europe and 84% of the authorised medicinal products listed a site in Europe. Larger differences were observed at the individual product level. Our analysis also yielded insights into the implementation of dual sourcing for over 400 authorised medicinal products.

Our study has three limitations. First, our cohort of ten high-use pharmaceutical substances out of over 13,000 [20] is unlikely to be representative of all medicines. For example, all of our substances are related to off-patent products. However, diverse supply chains were expected for high-use medicines because they are usually marketed by many MAHs. Also, the manufacturing of these off-patented medicines introduced complexity into the upstream supply chain due to increased outsourcing. [37] As these off-patent medicines are often expected to have a relatively robust supply chain, our approach highlights the minimum risks that the supply chain may face. The overdependency on one and the same manufacturer, as observed for some substances in this study, is expected more often for other pharmaceutical substances, such as substances for niche medicines. For these low-use pharmaceutical substances, dual-sourcing may not always be possible, e.g. because of a single supplier, or be particularly costly considering the small scale of production. [20, 26] For the ten substances in the present study, we also detected different patterns in the supply chains (isolated and intertwined supply chains), but we could not identify an overall sourcing strategy based on our data. Second, the included products were selected based on marketing authorisation in the Netherlands. Although MAHs may have different product portfolios in various countries, similar supply chain patterns are expected for products licenced in other countries in the EU or the European Economic Area (EEA), because most regulatory pathways in this region lead to authorisation in multiple member states or the entire EU or EEA. [38] Third, we focused only on API and FPP manufacturers and MAHs. Supply vulnerabilities can also be related to other factors, such as raw material and intermediate manufacturers, packaging sites, wholesalers, and distributors. The selected stakeholders are a crucial starting point, since they represent stringently regulated, core entities in the supply chain, and information on them could be extracted from a regulatory authority's database.

### Implications for policymakers and clinicians

Our granular analysis of the upstream pharmaceutical supply chains, displayed in Sankey diagrams, better facilitates the identification of supply chain vulnerabilities than numerical metrics. This facilitation will contribute to establishing effective measures to mitigate medicine shortages.

This study provides transparency in the API and FPP manufacturing and related MAHs of ten high-use pharmaceuticals. Although the information on authorised medicinal products and related MAHs was readily available in the public database of medicine agencies, the specific manufacturing sites were not disclosed. Product-specific information regarding supply chains is closely guarded by the MAHs as trade secrets or confidential commercial information. [39, 40] Even though authorities have access to information on the specific manufacturing sites, this information is not necessarily

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

337 available in a format enabling automated processing. [20] More transparency and standardised data  
338 on the supply chain, such as information on the APIs and FPPs that manufacturers prefer [41], would  
339 allow for an improved analysis of vulnerabilities by MAHs or authorities. Various stakeholders have  
340 advocated the need for further transparency [17, 20].

341 The EU is conducting an analysis of the supply chains for medicines on the EU list of critical  
342 medicines to identify vulnerabilities and to determine how these can best be addressed. [24] However,  
343 supply chains for pharmaceutical substances not included on the current EU list of critical medicines,  
344 also showed vulnerabilities, such as strong dependency on one and the same FPP manufacturer  
345 (omeprazole) and manufacturing sites mainly located outside Europe (simvastatin). Policymakers  
346 should not overlook substances that are not indicated as critical at a regional or national level since  
347 supply interruptions for non-critical substances may also have a considerable societal impact due to  
348 the significant number of patients affected. Our study showed that the supply chains for these ten  
349 substances may be vulnerable due to the lack of dual sourcing, and overdependency on a specific  
350 manufacturer.

351 We acknowledged that our cohort consisted of only ten pharmaceutical substances. Larger  
352 and more systematically differentiated samples (such as substances with established supply  
353 shortages) may yield different findings. We encourage future researchers to investigate this topic for  
354 complementary insights.

355 In addition to transparency concerning API and FPP manufacturers and MAHs, an analysis of  
356 the relationship between supply chain vulnerabilities and the occurrence of medicine shortages in daily  
357 practice could provide further insights to help establish secure, resilient pharmaceutical supply chains.

358 **CONCLUSION**

359 Our study on the supply chains of high-use generic pharmaceutical substances identified the need for  
360 a granular assessment of the interdependencies between API and FPP manufacturers and MAHs to  
361 identify upstream supply chain vulnerabilities. Policymakers should direct and amend their policies to  
362 effective measures to mitigate medicine shortages. They may also need to acquire a better  
363 understanding of the supply chains and its resilience. To aid, the method used in this study could be  
364 translated into a tool for public health resilience planning.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

## DATA AVAILABILITY STATEMENT

No additional data available, since data is related manufacturing locations of specific medicinal products and manufacturers, which is confidential information.

Access to the internal database of the Dutch Medicines Evaluation Board (MEB) was granted to DJP as part of her joint PhD trajectory with involvement of the MEB, Royal Dutch Pharmacists Association (KNMP) and University Utrecht. Conflict of interest and a confidentiality agreement was signed by DJP. Data on individual authorised medicinal products, manufacturers and MAHs are published in a de-identified manner. The manuscript was checked by the legal department of the MEB for confidential information prior to publishing.

## ACKNOWLEDGMENTS

The authors wish to thank the Dutch MEB for access to data in the MEB internal database and Rutger van den Broek (Dutch MEB) for retrieving the data from the internal database.

## FOOTNOTES

### Contributors

All authors conceived and designed the study. DJP performed the first analysis of the data and KN verified the study data. All authors contributed to the interpretation of the results. DJP and KN drafted the manuscript and prepared tables and figures. All authors read and critically reviewed and commented on each draft of the manuscript and approved the final manuscript for submission. DJP is the study guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

### Funding

This work was supported by the Dutch Medicines Evaluation Board and the Royal Dutch Pharmacists Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Competing interests

None declared

### Disclaimer

The views expressed in this article are the personal views of the authors and must not be understood or quoted as being made on behalf of or reflecting the position of the Dutch Medicines Evaluation Board or the Royal Dutch Pharmacists Association.

### Transparency

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and if relevant, registered) have been explained.

REFERENCES

1. World Health Organization. 2016. Addressing the Global Shortage of Medicines and Vaccines. WHA Resolution. Sixty-ninth World Health Assembly, WHA69.25. Available from: <https://www.who.int/publications/i/item/wha-69.25>. Accessed: Dec 21, 2024.

2. Huys I, Simoens S. 2013. European drug shortages: a call for action! Int J Pharm Pract. 21. 1-2. <https://doi.org/10.1111/ijpp.12012>.

3. Tucker EL, Cao Y, Fox ER, et al. 2020. The Drug Shortage Era: A Scoping Review of the Literature 2001–2019. Clinical Pharmacology & Therapeutics. 108. 1150-5. <https://doi.org/10.1002/cpt.1934>.

4. European Medicines Agency, Heads of Medicines Agencies. 2019. Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders (MAHs) in the Union (EEA). Available from: [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-detection-notification-shortages-medicinal-products-marketing-authorisation-holders-mahs\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-detection-notification-shortages-medicinal-products-marketing-authorisation-holders-mahs_en.pdf). Accessed: Dec 21, 2024.

5. Fink S. Drug Shortages Forcing Hard Decisions on Rationing Treatments. The New York Times. 2016 29 January, 2016.

6. Fox ER, Unguru Y. 2020. Oncology drug shortages in the USA — business as usual. Nature Reviews Clinical Oncology. 17. 128-9. <https://doi.org/10.1038/s41571-019-0318-x>.

7. Dutch Medicines Evaluation Board. 2023. Meldpunt Geneesmiddelen tekorten en -defecten 2022 [Report on Medicine shortages and defects notification centre 2022]. Available from: <https://www.cbg-meb.nl/documenten/rapporten/2023/03/07/rapportage-meldpunt-geneesmiddelen-tekorten-en--defecten-2022>. Accessed: Dec 21, 2024.

8. European Association of Hospital Pharmacists. 2020. 2019 EAHPh Medicines shortages report. Available from: [https://eahp.eu/wp-content/uploads/2024/03/eahp\\_2019\\_medicines\\_shortages\\_report.pdf](https://eahp.eu/wp-content/uploads/2024/03/eahp_2019_medicines_shortages_report.pdf). Accessed: Dec 21, 2024.

9. Robinson JC. 2001. Organizational economics and health care markets. Health Serv Res. 36. 177-89. PMC1089201.

10. Choo EK, Rajkumar SV. 2020. Medication Shortages During the COVID-19 Crisis: What We Must Do. Mayo Clin Proc. 95. 1112-5. <https://doi.org/10.1016/j.mayocp.2020.04.001>.

11. Cameron EE, Bushell MA. 2021. Analysis of drug shortages across two countries during pre-pandemic and pandemic times. Research in social & administrative pharmacy : RSAP. 17. 1570-3. <https://doi.org/10.1016/j.sapharm.2020.12.001>.

12. Vogler S. 2024. Tackling medicine shortages during and after the COVID-19 pandemic: Compilation of governmental policy measures and developments in 38 countries. Health Policy. 105030. <https://doi.org/10.1016/j.healthpol.2024.105030>.

13. Chapman S, Dedet G, Lopert R. 2022. Shortages of medicines in OECD countries. Available from: [https://www.oecd.org/en/publications/shortages-of-medicines-in-oecd-countries\\_b5d9e15d-en.html](https://www.oecd.org/en/publications/shortages-of-medicines-in-oecd-countries_b5d9e15d-en.html). Accessed: Dec 21, 2024.

14. Wagner SM, Grosse-Ruyken PT, Erhun F. 2018. Determinants of sourcing flexibility and its impact on performance. International Journal of Production Economics. 205. 329-41. <https://doi.org/10.1016/j.ijpe.2018.08.006>.

15. Gibson R. 2019. Exploring the Growing U.S. Reliance on China's Biotech and Pharmaceutical Products. Available from: <https://www.uscc.gov/sites/default/files/RosemaryGibsonTestimonyUSCCJuly152019.pdf>. Accessed: Dec 21, 2024.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



16. European Parliament. 2020. Shortage of medicines - how to deal with an emerging problem. Available from: [https://www.europarl.europa.eu/doceo/document/TA-9-2020-0228\\_EN.html](https://www.europarl.europa.eu/doceo/document/TA-9-2020-0228_EN.html). Accessed: Dec 21, 2024.
17. European Medicines Agency, Heads of Medicines Agencies. 2020. European medicines agencies network strategy to 2025. Available from: <https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network/european-medicines-agencies-network-strategy>. Accessed: Dec 21, 2024.
18. European Fine Chemicals Group. 2022. APIs Facts & Figures. Available from: [https://efcg.cefic.org/wp-content/uploads/2022/11/EFCG-2\\_Aug-APIs-FactsFigures-1.pdf](https://efcg.cefic.org/wp-content/uploads/2022/11/EFCG-2_Aug-APIs-FactsFigures-1.pdf). Accessed: Dec 21, 2024.
19. European Medicines Agency, Heads of Medicines Agencies. 2024. Good practices for industry for the prevention of human medicinal product shortages. Available from: [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages_en.pdf). Accessed: Dec 21, 2024.
20. European Commission: Directorate-General for Health and Food Safety. 2023. Vulnerabilities of the global supply chains of medicines - Structured Dialogue on the security of medicines supply. Available from: [https://health.ec.europa.eu/latest-updates/staff-working-document-vulnerabilities-global-supply-chains-medicines-structured-dialogue-security-2022-10-17\\_en](https://health.ec.europa.eu/latest-updates/staff-working-document-vulnerabilities-global-supply-chains-medicines-structured-dialogue-security-2022-10-17_en). Accessed: Dec 21, 2024.
21. Hedman L. 2016. Medicines shortages: global approaches to addressing shortages of essential medicines in health systems. WHO Drug Information. 30. 180-5.
22. European Commission: Directorate-General for Health and Food Safety, Jongh T, Becker D, et al. 2021. Future-proofing pharmaceutical legislation - Study on medicine shortages - Executive summary. Available from: <https://data.europa.eu/doi/10.2875/236176>. Accessed: Dec 21, 2024.
23. Food and Drug Administration. 2024. Executive Order 14017 on America's Supply Chains. Available from: <https://www.fda.gov/about-fda/reports/executive-order-14017-americas-supply-chains>. Accessed: Dec 21, 2024.
24. European Medicines Agency. 2023. Availability of critical medicines. Available from: <https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/medicine-shortages-availability-issues/availability-medicines-during-crises#union-list-of-critical-medicines-64278>. Accessed: Dec 21, 2024.
25. European Commission: Directorate-General for Health and Food Safety. 2024. Assessment of the supply chain vulnerabilities for the first tranche of the Union list of critical medicines: technical report. Available from: [https://health.ec.europa.eu/publications/assessment-supply-chain-vulnerabilities-first-tranche-union-list-critical-medicines-technical-report\\_en](https://health.ec.europa.eu/publications/assessment-supply-chain-vulnerabilities-first-tranche-union-list-critical-medicines-technical-report_en). Accessed: Dec 21, 2024.
26. European Commission: Directorate-General for Health and Food Safety. 2025. Proposal for a Critical Medicines Act. Available from: [https://health.ec.europa.eu/publications/proposal-critical-medicines-act\\_en](https://health.ec.europa.eu/publications/proposal-critical-medicines-act_en). Accessed: March 13 2025.
27. Tucker EL, Daskin MS. 2022. Pharmaceutical supply chain reliability and effects on drug shortages. Computers & Industrial Engineering. 169. 108258. <https://doi.org/10.1016/j.cie.2022.108258>.
28. Tucker EL, Daskin MS, Sweet BV, et al. 2020. Incentivizing resilient supply chain design to prevent drug shortages: policy analysis using two- and multi-stage stochastic programs. IIE Transactions. 52. 394-412. <https://doi.org/10.1080/24725854.2019.1646441>.



1  
2  
3 494 29. Doroudi R, Azghandi R, Feric Z, et al. An integrated simulation framework for  
4 495 examining resiliency in pharmaceutical supply chains considering human behaviors. 2018  
5 496 Winter Simulation Conference (WSC); 2018 9-12 Dec. 2018.  
6 497 30. Socal MP, Crane MA, Anderson GF. 2024. Global Production of Active Pharmaceutical  
7 498 Ingredients for US Generic Drugs Experiencing Shortages. JAMA. 331. 1763-5.  
8 499 <https://doi.org/10.1001/jama.2024.5296>.  
9 500 31. Postma DJ, De Smet PAGM, Notenboom K, et al. 2022. Impact of medicine shortages  
10 501 on patients - a framework and application in the Netherlands. BMC health services research.  
11 502 22. 1366. <https://doi.org/10.1186/s12913-022-08765-x>.  
12 503 32. Dutch Foundation for Pharmaceutical Statistics. 2022. Laxeermiddel macrogol telt  
13 504 meeste gebruikers in 2021 [Laxative macrogol has most users in 2021]. Available from:  
14 505 [https://www.sfk.nl/publicaties/PW/2022/laxeermiddel-macrogol-telt-meeste-gebruikers-in-](https://www.sfk.nl/publicaties/PW/2022/laxeermiddel-macrogol-telt-meeste-gebruikers-in-2021)  
15 506 [2021](https://www.sfk.nl/publicaties/PW/2022/laxeermiddel-macrogol-telt-meeste-gebruikers-in-2021). Accessed: Dec 21, 2024.  
16 507 33. Dutch Foundation for Pharmaceutical Statistics. Personal Communication. 2023.  
17 508 34. WHO Collaborating Centre for Drug Statistics Methodology. 2022. ATC - Structure  
18 509 and principles. Available from: [https://www.whocc.no/atc/structure\\_and\\_principles/](https://www.whocc.no/atc/structure_and_principles/).  
19 510 Accessed: Dec 21, 2024.  
20 511 35. Dutch Medicines Evaluation Board. 2024. Medicines Information Bank. Available  
21 512 from: <https://www.geneesmiddeleninformatiebank.nl>. Accessed: Dec 21, 2024.  
22 513 36. Socal MP, Ahn K, Greene JA, et al. 2023. Competition And Vulnerabilities In The  
23 514 Global Supply Chain For US Generic Active Pharmaceutical Ingredients. Health Aff  
24 515 (Millwood). 42. 407-15. <https://doi.org/10.1377/hlthaff.2022.01120>.  
25 516 37. European Medicines Agency, Heads of Medicines Agencies. 2023. Good practices for  
26 517 industry for the prevention of human medicinal product shortages. Available from:  
27 518 [https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages_en.pdf)  
28 519 [practices-industry-prevention-human-medicinal-product-shortages\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages_en.pdf). Accessed: 31  
29 520 May 2023.  
30 521 38. Heads of Medicines Agencies. Medicines Approval System. Available from:  
31 522 <https://www.hma.eu/about-hma/medicines-approval-system.html>. Accessed: Dec 21, 2024.  
32 523 39. Norwegian Directorate of Health. Meeting Report Antibiotic Shortages: Magnitude,  
33 524 Causes and Possible Solutions on 10-11 December 2018. Geneva, World Health  
34 525 Organization; 2019.; 2019. Report No.: WHO/MVP/EMP/IAU/2019.02.  
35 526 40. Drug Shortages Task Force. 2019. Drug Shortages: Root Causes and Potential  
36 527 Solutions. Available from: <https://www.fda.gov/media/131130/download>. Accessed: Dec 21,  
37 528 2024.  
38 529 41. USP. Medicines Supply Map. Available from: [https://www.usp.org/supply-](https://www.usp.org/supply-chain/medicine-supply-map)  
39 530 [chain/medicine-supply-map](https://www.usp.org/supply-chain/medicine-supply-map). Accessed: Dec 21, 2024.  
40 531


51 532 **FIGURE LEGENDS**

52 533 **Figure 1:** Selection of pharmaceutical substances with the largest number of patients in the Dutch outpatient  
53 534 setting and the related authorised medicinal products for analysis  
54 535 **Figure 2:** Number of authorised medicinal products with the corresponding number of manufacturing sites of  
55 536 active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs) according to the Dutch  
56 537 Medicines Evaluation Board database (n = 407).  
57 538 Red = one manufacturing site for APIs and FPPs; orange = one manufacturing site for APIs or FPPs; green = at  
58 539 least two manufacturing sites for APIs and FPPs.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

540 **Figure 3:** Exemplary supply chains for desloratadine (A) and simvastatin (B)  
541


For peer review only




Selection of pharmaceutical substances with the largest number of patients in the Dutch outpatient setting and the related authorised medicinal products for analysis

190x254mm (96 x 96 DPI)

# All authorized medicinal products (n = 407)





Exemplary supply chains for desloratadine (A) and simvastatin (B)

172x175mm (300 x 300 DPI)

## SUPPLEMENT TABLES AND FIGURES

### Supply chain vulnerabilities of high-use pharmaceuticals: an explorative cohort study

Doerine J Postma, Peter AGM De Smet, Aukje K Mantel-Teeuwisse, Hubert GM Leufkens, Kim Notenboom

**Table S1** – Overview of the included authorised medicinal products for outpatient use (n=407)

**Table S2** – Authorised medicinal products relying on one (and the same) API or FPP manufacturer


**Figure S1** – Number of authorised medicinal products with a manufacturing site per country - active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP)\*

**Figure S2** – Number of manufacturing sites per authorised medicinal product - active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP)

**Figure S3** – Supply chains per pharmaceutical substance



FIGURE S1 – NUMBER OF AUTHORISED MEDICINAL PRODUCTS WITH A MANUFACTURING SITE PER COUNTRY - ACTIVE PHARMACEUTICAL INGREDIENT (API) AND FINISHED PHARMACEUTICAL PRODUCT (FPP)\*



\* the sum of the products may be higher than the total number of products since a regulatory dossier for an authorised medicinal product may list manufacturers located in different countries

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

**FIGURE S2 – NUMBER OF MANUFACTURING SITES PER AUTHORISED MEDICINAL PRODUCT - ACTIVE PHARMACEUTICAL INGREDIENT (API) AND FINISHED PHARMACEUTICAL PRODUCT (FPP)**







FIGURE S3 – SUPPLY CHAINS PER PHARMACEUTICAL SUBSTANCE







Enseignement Supérieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.






TABLE S1 – OVERVIEW OF THE INCLUDED AUTHORISED MEDICINAL PRODUCTS FOR OUTPATIENT USE (N=407)

pharmaceutical substance	ATC 5th level code	therapeutic use	number of patients (% of population)	patented or off-patent	number of authorised medicinal products				number of marketing authorisation holders (MAHs)
					total	oral	inhalable	rectal	
amoxicillin	J01CA04	bacterial infection	815,000 (4.7)	off-patent	32	32			9
colecalfiferol	A11CC05	vitamin D deficiency	1,005,000 (5.8)	off-patent	82	82			24
desloratadine	R06AX27	allergy	740,000 (4.3)	off-patent	34	34			17
diclofenac	M01AB05	pain	815,000 (4.7)	off-patent	29	21		8	11
levonorgestrel/ethinylestradiol	G03AA07	contraception	1,000,000 (5.7)	off-patent	21	21			10
metoprolol	C07AB02	high blood pressure	1,010,000 (5.8)	off-patent	34	34			10
omeprazole	A02BC01	(prevention of) stomach ache	1,290,000 (7.4)	off-patent	85	85			19
pantoprazole	A02BC02	(prevention of) stomach ache	1,285,000 (7.4)	off-patent	33	33			15
salbutamol	R03AC02	asthma and COPD	780,000 (4.5)	off-patent	21		21		8
simvastatin	C10AA01	high cholesterol	845,000 (4.8)	off-patent	36	36			10
Total			6,475,000* (37)		407	378	29	8	70**

\* The total (unique) number of patients is lower than the sum of the number of patients since nearly half of patients used more than one pharmaceutical substance.

\*\*The total number of MAHs is lower than the sum of the MAHs since one MAH can market authorised medicinal products for different substances.



**TABLE S2 – AUTHORISED MEDICINAL PRODUCTS RELYING ON ONE (AND THE SAME) API OR FPP MANUFACTURER**

**A. Active pharmaceutical ingredient (API) manufacturer**

pharmaceutical substance	number of authorised medicinal products		
	total	one API manufacturer	one and the same API manufacturer
amoxicillin	32	24 (75%)	16 (50%)
colecalfiferol	82	64 (78%)	34 (41%)
desloratadine	34	11 (32%)	3 (9%)
diclofenac	29	20 (69%)	12 (41%)
levonorgestrel / ethinylestradiol	21	15 (71%)	7 (33%)
		10 (48%)	10 (48%)
metoprolol	34	12 (35%)	8 (24%)
omeprazole	85	20 (24%)	8 (9%)
pantoprazole	33	3 (9%)	2 (6%)
salbutamol	21	8 (38%)	1 (5%)
simvastatin	36	9 (25%)	9 (25%)

**B. Finished pharmaceutical product (FPP) manufacturer**

pharmaceutical substance	number of authorised medicinal products		
	total	one FPP manufacturer	one and the same FPP manufacturer
amoxicillin	32	17 (53%)	6 (19%)
colecalfiferol	82	44 (54%)	7 (9%)
desloratadine	34	29 (85%)	6 (7%)
diclofenac	29	15 (52%)	4 (14%)
levonorgestrel / ethinylestradiol	21	20 (95%)	8 (38%)
metoprolol	34	22 (65%)	9 (26%)
omeprazole	85	82 (86%)	39 (46%)
pantoprazole	33	11 (31%)	5 (14%)
salbutamol	21	18 (86%)	5 (24%)
simvastatin	36	5 (31%)	3 (8%)